The PD-MED trial compared different first-line treatment strategies in newly diagnosed patients, and those allocated to MAO-B inhibitors or dopamine agonists were prescribed additional levodopa to optimize symptoms as necessary. This evidence concerns the gene MAOB and Parkinson disease.